Oluwatoyosi A Onwuemene1, Nicole D Zantek2, Marian A Rollins-Raval3, Jay S Raval3, Joseph E Kiss4, Tina S Ipe5, Maragatha Kuchibhatla6, Monica B Pagano7, Edward C C Wong8,9. 1. Division of Hematology, Department of Medicine, Duke University, Durham, North Carolina. 2. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 3. Department of Pathology, University of New Mexico, Albuquerque, New Mexico. 4. Vitalant Northeast Division Blood Services, and University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas. 6. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina. 7. Department of Laboratory Medicine, University of Washington, Seattle, Washington. 8. Department of Coagulation, Quest Diagnostics, Nichols Institute, Chantilly, Virginia. 9. Department of Pediatrics and Pathology, George Washington School of Medicine and Health Sciences, Washington, District of Columbia.
Abstract
INTRODUCTION: Anti-heparin/platelet factor 4 antibody immune complexes resulting from heparin-induced thrombocytopenia (HIT) are removed by therapeutic plasma exchange (TPE). We sought to define TPE in HIT practice patterns using an international survey. METHODS: A 31-item online survey was disseminated through the American Society for Apheresis. After institutional duplicate responses were eliminated, a descriptive analysis was performed. RESULTS: The survey was completed by 94 respondents from 78 institutions in 18 countries. Twenty-nine institutions (37%) used TPE for HIT (YES cohort) and 49 (63%) did not (NO cohort). Most NO respondents (65%) cited "no requests received" as the most common reason for not using TPE. Of the 29 YES respondents, 10 (34%) gave incomplete information and were excluded from the final analysis, leaving 19 responses. Of these, 18 (95%) treated ≤10 HIT patients over a 2-year period. The most common indications were cardiovascular surgery (CS; 63%) and HIT-associated thrombosis (HT; 26%). The typical plasma volume processed was 1.0 (63% CS and 58% HT). For CS, the typical replacement fluid was plasma (42%) and for HT, it was determined on an individual basis (32%). For CS, patients were treated with a set number of TPE procedures (37%) or laboratory/clinical response (37%). For HT, the number of TPE procedures typically depended on laboratory/clinical response (42%). CONCLUSION: In a minority of responding institutions, TPE is most commonly used in HIT to prophylactically treat patients who will undergo heparin re-exposure during CS. Prospective studies are needed to more clearly define the role of TPE in HIT.
INTRODUCTION: Anti-heparin/platelet factor 4 antibody immune complexes resulting from heparin-induced thrombocytopenia (HIT) are removed by therapeutic plasma exchange (TPE). We sought to define TPE in HIT practice patterns using an international survey. METHODS: A 31-item online survey was disseminated through the American Society for Apheresis. After institutional duplicate responses were eliminated, a descriptive analysis was performed. RESULTS: The survey was completed by 94 respondents from 78 institutions in 18 countries. Twenty-nine institutions (37%) used TPE for HIT (YES cohort) and 49 (63%) did not (NO cohort). Most NO respondents (65%) cited "no requests received" as the most common reason for not using TPE. Of the 29 YES respondents, 10 (34%) gave incomplete information and were excluded from the final analysis, leaving 19 responses. Of these, 18 (95%) treated ≤10 HITpatients over a 2-year period. The most common indications were cardiovascular surgery (CS; 63%) and HIT-associated thrombosis (HT; 26%). The typical plasma volume processed was 1.0 (63% CS and 58% HT). For CS, the typical replacement fluid was plasma (42%) and for HT, it was determined on an individual basis (32%). For CS, patients were treated with a set number of TPE procedures (37%) or laboratory/clinical response (37%). For HT, the number of TPE procedures typically depended on laboratory/clinical response (42%). CONCLUSION: In a minority of responding institutions, TPE is most commonly used in HIT to prophylactically treat patients who will undergo heparin re-exposure during CS. Prospective studies are needed to more clearly define the role of TPE in HIT.
Authors: Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Richard H Aster; Anand Padmanabhan Journal: Blood Date: 2017-12-19 Impact factor: 22.113
Authors: A Cuker; G Arepally; M A Crowther; L Rice; F Datko; K Hook; K J Propert; D J Kuter; T L Ortel; B A Konkle; D B Cines Journal: J Thromb Haemost Date: 2010-12 Impact factor: 5.824
Authors: Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais Journal: Blood Date: 2004-08-10 Impact factor: 22.113
Authors: David J Kuter; Barbara A Konkle; Taye H Hamza; Lynne Uhl; Susan F Assmann; Joseph E Kiss; Richard M Kaufman; Nigel S Key; Bruce S Sachais; John R Hess; Paul Ness; Keith R McCrae; Cindy Leissinger; Ronald G Strauss; Janice G McFarland; Ellis Neufeld; James B Bussel; Thomas L Ortel Journal: Am J Hematol Date: 2017-04-26 Impact factor: 10.047